top of page

A Novel Treatment For Platinum-Resistant Ovarian Cancer

Writer's picture: Women's Cancer Research FoundationWomen's Cancer Research Foundation


Every year in the U.S., 22,000 to 24,000 women are diagnosed with ovarian cancer. Patient survival depends upon the responses to chemotherapy. Recently, study results involving mirvetuximab soravtansine, an antibody drug conjugate that targets folate receptor alpha expression (the expression of folate receptor alpha is encountered in most ovarian cancers and is indicative of tumor aggressiveness), has demonstrated significant clinical efficacy in heavily-pretreated ovarian cancer patients.


Every year in the U.S., 22,000 to 24,000 women are diagnosed with ovarian cancer.

In the Soraya study, a total of 106 platinum-resistant ovarian cancer patients who were treated with a median of three prior therapies, exhibited a response rate of 32.4% (the tumors deceased in size) for a median duration of 5.9 months following treatment with mirvetuximab soravtansine. Mirvetuximab soravtansine was also fairly well-tolerated, although 41% of patients experienced blurred vision related to the treatment and keratopathy, a disease of the cornea, occurred in 35% of patients; the ocular deficits were all reversible. Mirvetuximab soravtansine may confer significant survival benefits in ovarian cancer, especially in patients who exhibit high levels of folate receptor alpha expression


About Women’s Cancer Research Foundation

The Women’s Cancer Research Foundation (WCRF) is one of the most active research organizations in the nation. We are dedicated to studying and evaluating novel treatments for women afflicted with breast, ovarian, endometrial, and cervical cancers. The WCRF persistently endeavors to make a difference in women’s lives by offering them hope, strength, and progress.



Laguna Beach, CA 92651

PH: (949) 642-5165


Follow Us On Social Media:


19 views0 comments

Kommentare


FORMERLY KNOWN AS THE NANCY YEARY WOMEN'S CANCER RESEARCH FOUNDATION
IN MEMORY OF NANCY AND BOB YEARY

ABOUT US 

Since 1985, the physicians and researchers at the WCRF have been at the forefront of pioneering clinical research, aimed at enhancing cure rates among women diagnosed with breast, ovarian, uterine, and cervical cancers. WCRF actively engages in designing, conducting, and disseminating groundbreaking research focused on cutting-edge medical treatments.


Furthermore, WCRF serves as a vital hub for both foundational and applied research, as well as education, pertaining to the latest advancements in the treatment of breast and gynecologic cancers. In addition to conducting and publishing original research, the WCRF, provides valuable clinical information to physicians and patients alike.
 

 

Subscribe to Our Newsletter

Thanks for submitting!

CONTACT 

T: 949-642-5165

F: 949-646-7157

​

​

699 Diamond Street
Laguna Beach, CA 92651

  • Womens Cancer Research Foundation on X
  • LinkedIn
  • Facebook
  • YouTube
  • Instagram
Wpmen's Cancer Research Foundation

© 2025 Women's Cancer Research Foundation All rights reserved.

Website design by Tribe of Digital Natives

bottom of page